- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00081224
Neoadjuvant Celecoxib and Capecitabine Combined With Pelvic Irradiation in Treating Patients With Stage II or Stage III Adenocarcinoma (Cancer) of the Rectum
A Phase II Trial Of Celecoxib (Celebrex) And Capecitabine (Xeloda) Combined With Pelvic Irradiation As Neoadjuvant Treatment Of Stage II or III Adenocarcinoma Of The Rectum
RATIONALE: Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Celecoxib may also make tumor cells more sensitive to chemotherapy and radiation therapy. Giving celecoxib with capecitabine and radiation therapy before surgery may shrink the tumor so that it can be removed.
PURPOSE: This phase II trial is studying how well giving neoadjuvant celecoxib together with capecitabine and pelvic irradiation works in treating patients with stage II or stage III adenocarcinoma (cancer) of the rectum.
연구 개요
상세 설명
OBJECTIVES:
Primary
- Determine the pathological complete response rate in patients with stage II or III adenocarcinoma of the rectum treated with neoadjuvant celecoxib and capecitabine in combination with pelvic irradiation.
Secondary
- Determine the safety and tolerability of this regimen in these patients.
- Determine the rectal function of patients treated with this regimen.
- Determine the time to recurrence or progression and survival time of patients treated with this regimen.
- Correlate cellular and molecular markers in pretreatment tumor samples with response in patients treated with this regimen.
OUTLINE: This is a multicenter study.
- Neoadjuvant chemoradiotherapy: Patients receive oral celecoxib twice daily on days 1-7 and oral capecitabine twice daily on days 1-5. Patients undergo pelvic radiotherapy once daily on days 1-5. Courses repeat weekly for 5.5 weeks.
- Surgery: Patients undergo surgery 4-6 weeks after completion of neoadjuvant chemoradiotherapy.
- Adjuvant chemotherapy: Patients with a curative resection receive oral capecitabine twice daily on days 1-14. Treatment repeats every 21 days for up to 4 courses.
Treatment continues in the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months for 1 year and then every 6 months for 4 years.
연구 유형
등록 (실제)
단계
- 2 단계
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
DISEASE CHARACTERISTICS:
Histologically confirmed rectal adenocarcinoma
- Clinical stage T3, N0, M0 OR any T, N1-3, M0 disease
Treatment with neoadjuvant chemotherapy and pelvic radiotherapy is indicated
- All disease must be encompassable within standard pelvic radiotherapy fields
- Distal border of the tumor must be at or below* the peritoneal reflection, defined as within 12 cm of the anal verge by endoscopy NOTE: *If a portion of the tumor is below the peritoneal reflection at the time of surgery, patients are eligible regardless of the distance of the tumor determined at endoscopy
Tumor must be determined to be clinically resectable
- Tumor may not be clinically fixed
- Negative margins by routine examination of an unanesthetized patient
- Transmural penetration of tumor through the muscularis propria by CT scan, endorectal ultrasound, or MRI
No distant metastatic disease
No evidence of tumor outside the pelvis, including any of the following:
- Metastatic inguinal lymphadenopathy
- Peritoneal seeding
- Liver metastases
PATIENT CHARACTERISTICS:
Age
- 18 and over
Performance status
- ECOG 0-1
Life expectancy
- At least 6 months
Hematopoietic
- Absolute neutrophil count ≥ 1,500/mm^3
- Platelet count ≥ 100,000/mm^3
Hepatic
- Bilirubin ≤ upper limit of normal (ULN)
- AST ≤ 3 times ULN
- Alkaline phosphatase ≤ 4 times ULN if AST < ULN
Renal
- Creatinine clearance ≥ 30 mL/min
- No renal impairment
Cardiovascular
- No congestive heart failure
- No symptomatic coronary artery disease
- No uncontrolled cardiac arrhythmias
- No myocardial infarction
- No history of transient ischemic attacks or stroke
- No other clinically significant cardiac disease
Gastrointestinal
- No bleeding peptic ulcer disease within the past 12 months
- No lack of physical integrity of the upper gastrointestinal tract
- No malabsorption syndrome
- No active inflammatory bowel disease
- Must be able to swallow study drugs
Other
- No dihydropyrimidine dehydrogenase deficiency
- No history of uncontrolled seizures
- No CNS disorders
- No clinically significant psychiatric illness that would preclude study compliance or giving informed consent
- No other malignancy within the past 5 years except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
- No known sensitivity to NSAIDs, sulfonamides, or aspirin
- No other serious medical illness that would preclude study treatment
- No other conditions that would preclude study participation
- Must be able to tolerate major surgery that may include abdominal-perineal resection
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 30 days after study treatment
PRIOR CONCURRENT THERAPY:
Biologic therapy
- Not specified
Chemotherapy
- See Disease Characteristics
- No prior systemic anticancer chemotherapy
Endocrine therapy
- Not specified
Radiotherapy
- See Disease Characteristics
- No prior radiotherapy to the pelvis
Surgery
- See Disease Characteristics
- More than 3 weeks since prior major surgery and recovered
Other
- At least 7 days since prior nonsteroidal anti-inflammatory drugs (NSAIDs), including aspirin
- No other concurrent investigational drugs
- No other concurrent anticancer treatment
- No concurrent NSAIDs
- No concurrent primary prophylactic therapy for hand-foot syndrome
- No concurrent loperamide prophylaxis for diarrhea
- No concurrent sorivudine or brivudine
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: celecoxib + capecitabine + radiation + surgery
Neoadjuvant chemoradiotherapy: Patients receive oral celecoxib twice daily on days 1-7 and oral capecitabine twice daily on days 1-5. Patients undergo pelvic radiotherapy once daily on days 1-5. Courses repeat weekly for 5.5 weeks. Surgery: Patients undergo surgery 4-6 weeks after completion of neoadjuvant chemoradiotherapy. Adjuvant chemotherapy: Patients with a curative resection receive oral capecitabine twice daily on days 1-14. Treatment repeats every 21 days for up to 4 courses. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 1 year and then every 6 months for 4 years. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
Proportion of successes
기간: Up to 5 years
|
Up to 5 years
|
2차 결과 측정
결과 측정 |
기간 |
|---|---|
|
생존 시간
기간: 최대 5년
|
최대 5년
|
|
활착
기간: 최대 5년
|
최대 5년
|
|
Time-to event analyses
기간: Up to 5 years
|
Up to 5 years
|
|
Time to disease progression/recurrence
기간: Up to 5 years
|
Up to 5 years
|
|
Time to recurrence
기간: Up to 5 years
|
Up to 5 years
|
|
Time to first progression
기간: Up to 5 years
|
Up to 5 years
|
|
Bowel function as measured by the Patient Bowel Function (Uniscale) Questionnaire, the FACT Diarrhea Subscale and the Mayo Bowel Function Questionnaire
기간: Up to 5 years
|
Up to 5 years
|
공동 작업자 및 조사자
수사관
- 연구 의자: Frank Sinicrope, MD, Mayo Clinic
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- NCCTG-N0346
- NCI-2012-02582 (레지스트리 식별자: CTRP (Clinical Trials Reporting System))
- CDR0000360666 (레지스트리 식별자: PDQ (Physician Data Query))
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .